Urgent

Mixed cryoglobulinaemia (cryoglobulinaemic vasculitis)

mixed-cryoglobulinaemia · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Small-to-medium vessel immune-complex vasculitis caused by type II/III cryoglobulins (polyclonal IgG bound to an IgM rheumatoid factor). Most commonly HCV-associated (80-90%); also HBV, HIV, autoimmune disease (SLE, Sjogren), lymphoproliferative disorders, and rarely idiopathic. Usually chronic/smouldering - Meltzer triad of palpable purpura, weakness, and arthralgia - but can present as rapidly progressive, life-threatening disease (RPGN, GI/pulmonary/CNS vasculitis, digital ischaemia). ED role: recognise it, assess organ threat, start the work-up, and treat severe disease.

Red flags

  • Rapidly progressive glomerulonephritis / AKI
  • Diffuse alveolar haemorrhage or respiratory failure
  • GI vasculitis (abdominal pain, GI bleeding)
  • CNS vasculitis (stroke, acute cognitive change)
  • Digital ischaemia threatening amputation or necrotic ulcers
  • Progressive mononeuritis multiplex (foot/wrist drop)
  • Symptomatic hyperviscosity; severe hypertension

Assessment

Differential diagnosis

  • ANCA-associated vasculitis (GPA/MPA/EGPA)
  • IgA vasculitis (Henoch-Schonlein purpura)
  • Drug-induced/hypersensitivity and infection-related vasculitis (endocarditis, poststreptococcal)
  • Connective-tissue disease vasculitis (SLE, RA, Sjogren)
  • Cutaneous small-vessel vasculitis
  • Infective mimics (EBV, rickettsial, Lyme, babesiosis, brucellosis, endocarditis)
  • TTP / other thrombotic microangiopathy; sepsis with purpura

Investigations

  • Serum cryoglobulins - blood drawn into PREWARMED (37 C) tubes WITHOUT anticoagulant and kept warm to the lab (false negatives if not); cryocrit >0.5-1% or cryoglobulin >2-5 mg/dL is significant (30-40% of type II undetectable at presentation)
  • Rheumatoid factor (usually high) and complement (C4 markedly low - often the most prominent finding; C3/CH50 less so)
  • CBC - note temperature-dependent spurious WBC/platelet elevation from cryoglobulin particles
  • Creatinine and urinalysis with sediment (MPGN - haematuria/proteinuria); LFTs
  • HCV, HBV, and HIV serologies in all patients
  • ANA, anti-dsDNA/ENA, and ANCA (to distinguish ANCA-associated vasculitis)
  • SPEP/immunofixation and serum free light chains (type I / lymphoproliferative disease)
  • Tissue biopsy (skin/kidney) in uncertainty - leukocytoclastic vasculitis / MPGN with intraluminal immune thrombi

Management

  • Assess severity/organ threat: skin ulcer or necrosis, RPGN, GI vasculitis, diffuse alveolar haemorrhage/respiratory failure, CNS vasculitis, progressive neuropathy, digital ischaemia
  • Mild disease: symptomatic care (NSAIDs, pain and wound care, avoid cold) plus treat the underlying cause
  • Moderate-to-severe disease: immunosuppression (high-dose glucocorticoids + rituximab) and treat the underlying disease
  • Timing of antivirals: for HCV, immunosuppression is usually started first; for HIV and HBV, start antiviral before or at the same time as immunosuppression
  • Plasma exchange for the few critical scenarios (below)
  • Pneumocystis prophylaxis for patients on high-dose steroids/immunosuppression; admit severe disease

Drugs & doses

Prednisone (low-dose) 10 mg PO daily — Mild disease arthralgia if NSAIDs inadequate
Colchicine or dapsone — Non-ulcerating skin disease (mild)
Hydroxychloroquine max 5 mg/kg/day PO — Overt arthritis (mild)
Neuropathic agents (amitriptyline/nortriptyline, duloxetine, gabapentin, pregabalin) — Mild sensory neuropathy; avoid opioids
Methylprednisolone 1000 mg IV daily 3 days — Pulse therapy for life-threatening disease, then switch to oral prednisone
Prednisone (oral regimen) 1 mg/kg/day (max 80 mg) x2-4 weeks, then 40 mg/day x2 weeks, then 20 mg/day x2-4 weeks, then taper 5 mg/week PO — Example source regimen for moderate-severe disease
Rituximab 1 g IV then 1 g on day 14, OR 375 mg/m2 weekly x4 IV — Preferred immunosuppressant (with glucocorticoids). Use 375 mg/m2 x4 if high-titre RF, very low C4, or cryocrit >=10% - 1 g dosing risks fatal acute serum sickness from IgG-IgM interaction
Cyclophosphamide IV 750 mg/m2 monthly pulses, or oral 2 mg/kg/day x2 months — Alternative if rituximab unavailable/failed/not tolerated; risk of enhancing viral replication in HCV/HBV
Plasma exchange — Limited to symptomatic hyperviscosity, life-threatening disease (diffuse alveolar haemorrhage/respiratory failure, acute intestinal vasculitis, RPGN needing dialysis), refractory skin ulcers, or high cryocrit >=10% before rituximab (2-3 sessions). ~1 plasma volume (3 L)/session; WARMED 5% albumin replacement (FFP if recent kidney biopsy); warm room/tubing; combine with B-cell therapy
Trimethoprim-sulfamethoxazole one DS tablet daily or 3x/week (or one SS daily) PO — Pneumocystis prophylaxis during high-dose steroids/immunosuppression

Disposition

Admit organ- or life-threatening disease (urgent nephrology/rheumatology, immunosuppression +/- plasma exchange; ICU for DAH, CNS, or GI vasculitis). Mild/smouldering disease: outpatient rheumatology with symptomatic care and underlying-cause work-up.

Complications & pitfalls

  • MPGN / chronic kidney disease
  • Progressive peripheral neuropathy
  • Skin ulceration, necrosis, gangrene
  • GI, pulmonary, or CNS vasculitis; hyperviscosity
  • Markedly increased risk of B-cell non-Hodgkin lymphoma (especially HCV-associated)
  • Rituximab-associated flare / acute serum sickness

Exam pearls

  • Clue cluster: palpable purpura + low C4 + high RF, worsened by cold
  • Cryocrit does NOT correlate with severity or treatment response - treat by organ involvement, not cryocrit
  • Draw cryoglobulins in prewarmed anticoagulant-free tubes kept warm (false negatives common; 30-40% of type II undetectable at presentation)
  • Spurious CBC WBC/platelet elevation if the sample cools
  • Test HCV/HBV/HIV in everyone; for HIV and HBV start antiviral before or with immunosuppression

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.